fibrosis as an experimental marker of efficacy outcomes in myelofibrosis
Published 1 year ago • 220 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
2:04
preview of our new video tutorial “how to diagnose primary myelofibrosis”
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:06
the importance of early intervention in myelofibrosis
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
4:22
what do patients with myelofibrosis need to know?
-
3:33
a novel composite endpoint of toxicity and pfs in patients with r/r fl treated with axi-cel
-
1:38
an overview of the practical challenges in approaching r/r amyloidosis
-
0:56
fostering a multidisciplinary approach to treating amyloidosis
-
3:12
an update on allohsct in scd
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
6:05
the flipi24 model for identifying poor outcomes in non-immunochemotherapy treated fl
-
1:13
molecular mrd as a prognostic marker for aml patients with mutated cebpa
-
1:24
detection of circulating ttr aggregates: a potential novel biomarker for attr amyloidosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors